ST Pharm Co.,Ltd. (237690.KQ)

KRW 84900.0

(-4.61%)

Market Cap (In KRW)

1709.48 Billion

Revenue (In KRW)

284.99 Billion

Net Income (In KRW)

19.58 Billion

Avg. Volume

478.69 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
59900.0-120800.0
PE
-
EPS
-
Beta Value
0.90909
ISIN
KR7237690003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Mr. Geun-Jo Im Ph.D.
Employee Count
-
Website
http://www.stpharm.co.kr
Ipo Date
2016-06-23
Details
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.